Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization

Molly Braun, Zenab T. Khan, Mohammad Badruzzaman Khan, Manish Kumar, Ayobami Ward, Bhagelu Ram Achyut, Ali Syed Arbab, David C Hess, MD Nasrul Hoda, Babak Baban, Krishnan Michael Dhandapani, Kumar Vaibhav

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1–5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation.

Original languageEnglish (US)
Pages (from-to)224-237
Number of pages14
JournalBrain, Behavior, and Immunity
Volume68
DOIs
StatePublished - Feb 1 2018

Fingerprint

Cannabinoid Receptors
Macrophages
Endocannabinoids
Cerebrovascular Circulation
Anti-Inflammatory Agents
Wounds and Injuries
Myeloid Cells
Edema
Up-Regulation
Traumatic Brain Injury
Ligands
Inflammation
Lipids

Keywords

  • Cannabinoid receptor 2
  • Controlled cortical impact
  • Inflammation
  • Macrophage
  • Marijuana

ASJC Scopus subject areas

  • Immunology
  • Endocrine and Autonomic Systems
  • Behavioral Neuroscience

Cite this

@article{66723c8d65794e18ada4d9546b78e615,
title = "Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization",
abstract = "Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1–5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation.",
keywords = "Cannabinoid receptor 2, Controlled cortical impact, Inflammation, Macrophage, Marijuana",
author = "Molly Braun and Khan, {Zenab T.} and Khan, {Mohammad Badruzzaman} and Manish Kumar and Ayobami Ward and Achyut, {Bhagelu Ram} and Arbab, {Ali Syed} and Hess, {David C} and Hoda, {MD Nasrul} and Babak Baban and Dhandapani, {Krishnan Michael} and Kumar Vaibhav",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.bbi.2017.10.021",
language = "English (US)",
volume = "68",
pages = "224--237",
journal = "Brain, Behavior, and Immunity",
issn = "0889-1591",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Selective activation of cannabinoid receptor-2 reduces neuroinflammation after traumatic brain injury via alternative macrophage polarization

AU - Braun, Molly

AU - Khan, Zenab T.

AU - Khan, Mohammad Badruzzaman

AU - Kumar, Manish

AU - Ward, Ayobami

AU - Achyut, Bhagelu Ram

AU - Arbab, Ali Syed

AU - Hess, David C

AU - Hoda, MD Nasrul

AU - Baban, Babak

AU - Dhandapani, Krishnan Michael

AU - Vaibhav, Kumar

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1–5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation.

AB - Inflammation is an important mediator of secondary neurological injury after traumatic brain injury (TBI). Endocannabinoids, endogenously produced arachidonate based lipids, have recently emerged as powerful anti-inflammatory compounds, yet the molecular and cellular mechanisms underlying these effects are poorly defined. Endocannabinoids are physiological ligands for two known cannabinoid receptors, CB1R and CB2R. In the present study, we hypothesized that selective activation of CB2R attenuates neuroinflammation and reduces neurovascular injury after TBI. Using a murine controlled cortical impact (CCI) model of TBI, we observed a dramatic upregulation of CB2R within infiltrating myeloid cells beginning at 72 h. Administration of the selective CB2R agonist, GP1a (1–5 mg/kg), attenuated pro-inflammatory M1 macrophage polarization, increased anti-inflammatory M2 polarization, reduced edema development, enhanced cerebral blood flow, and improved neurobehavioral outcomes after TBI. In contrast, the CB2R antagonist, AM630, worsened outcomes. Taken together, our findings support the development of selective CB2R agonists as a therapeutic strategy to improve TBI outcomes while avoiding the psychoactive effects of CB1R activation.

KW - Cannabinoid receptor 2

KW - Controlled cortical impact

KW - Inflammation

KW - Macrophage

KW - Marijuana

UR - http://www.scopus.com/inward/record.url?scp=85032343375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032343375&partnerID=8YFLogxK

U2 - 10.1016/j.bbi.2017.10.021

DO - 10.1016/j.bbi.2017.10.021

M3 - Article

VL - 68

SP - 224

EP - 237

JO - Brain, Behavior, and Immunity

JF - Brain, Behavior, and Immunity

SN - 0889-1591

ER -